DIRS.INFO The most relevant business & tech news

Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. European generic drugmakers say the tender system and regulated prices have fuelled a race to the bottom, and European firms are being undercut by suppliers from Asia. BRUSSELS, WE HAVE A PROBLEMThe European Medicines Agency (EMA) and European Union lawmakers acknowledge there is a problem. Half the generic medicines sold in Spain are priced below 1.60 euros per box or bottle, the country's generics manufacturing association said. But companies with smaller market shares, such as Israel's Teva (TEVA.TA), which has 5% of the region's amoxicillin market according to Medicines for Europe, are constrained.

LONDON/GENEVA, Feb 1 (Reuters) - Governments may have to reserve drugs and vaccines for the World Health Organization to distribute in poorer countries to avoid a repeat of the "catastrophic failure" during the COVID-19 pandemic, according to an early draft of a global pandemic agreement. The agreement, which is commonly known as the pandemic treaty, has been drawn up by WHO member states and will now go through a lengthy negotiating process before being finalised. Talks on the draft treaty will begin on Feb. 27 and are set to continue to 2024. However, there will be "heat and opposition" in the negotiations ahead, particularly around the intellectual property provisions, said James Love, director of the NGO Knowledge Ecology International. The draft also calls for a new WHO Global Pandemic Supply Chain and Logistics Network to ensure better and fairer distribution of counter-measures, as well as a global compensation scheme for vaccine injuries.

☆ Some bloodstream infection bacteria grew resistant to last-resort drugs in 2020 - WHO
▼ + stars: | 2022-12-09 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

LONDON, Dec 9 (Reuters) - Increased drug resistance in bacteria causing bloodstream infections, including against last-resort antibiotics, was seen in the first year of the coronavirus pandemic, a World Health Organization report based on data from 87 countries in 2020 showed. High levels (above 50%) of resistance have been reported in bacteria that typically cause life-threatening bloodstream infections in hospitals such as Klebsiella pneumoniae and Acinetobacter spp, report authors highlighted on Friday. These infections often require treatment with 'last-resort' antibiotics, drugs that are used when all other antibiotics fail. About 8% of bloodstream infections caused by Klebsiella pneumoniae grew resistant to a vital last-resort group of drugs called carbapenems, the report said. Rates of antimicrobial resistance (AMR) remain very high, but last-resort antibiotics are only just starting to lose potency, said Dr Carmem Pessoa-Silva, the lead for WHO Global Antimicrobial Resistance Surveillance System, in a media conference.

LONDON, Nov 17 (Reuters) - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make to fight future pandemics, under new rules being drawn up by the World Health Organization and reviewed by Reuters. During the pandemic, many deals that governments made with pharmaceutical companies have been kept confidential, giving them little scope to hold drugmakers accountable. A spokesperson for the WHO said it was member states that were driving the current process towards a new agreement. "The process is open, transparent, and with the input from other stakeholders, including any interested stakeholders and public, able to submit comments at public consultations." The draft will be presented to them in full in a meeting on Friday, after being circulated earlier in the week.

☆ Până la mijlocul anului următor ar putea fi disponibile zece vaccinuri anti-COVID-19
▼ + stars: | 2020-11-27 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +2 min

Vaccinurile dezvoltate de Pfizer şi BioNtech, precum şi de Moderna şi AstraZeneca au demonstrat rezultate promiţătoare în testele clinice, însă nu se pune problema de "a o lua pe scurtătură", a spus Thomas Cueni, directorul general al Federaţiei Internaţionale a Producătorilor şi Asociaţiilor Farmaceutice (IFPMA). "Până acum au fost lansate trei vaccinuri şi toate trei au fost un succes. Mă aşteaptă să vedem rezultate pozitive similare de la Novavax şi multe alte firme Sanofi Pasteur, GSK şi Merck", a spus Thomas Cueni. În consecinţă, ar fi o greşeală să fie eliminată protecţia de care beneficiază licenţele şi să se încerce producţia unor vaccinuri atât de complexe fără personal calificat şi proceduri de calitate a controlului. "Sperăm că până la vară vom avea, probabil, 10 vaccinuri care îşi vor fi dovedit valoarea.

Persons: Thomas Cueni, Johnson & Johnson . Mă, Thomas Cueni.India, Cueni Organizations: AstraZeneca, Johnson &, biotech Locations: Africa de Sud, SUA, Europa, Elveţia

Search resuls for: "Cueni"

5 mentions found